Oncology Immunotherapy exploits virus's ability to replicate selectively and kill tumor tissue while at the same time regulate the specific immune response of a patient The first oncolytic virus to demonstrate a clinical benefit in patients with melanoma is genetically modified herpes simplex virus type I i.e. Talimogene laherparepvec (T-VEC).
North America is leading in the oncolytic virus immunotherapy market globally, according to Skin Cancer Foundation Statistics, Globally 132,000 melanoma skin cancers occur each year. One in every three cancers diagnosed is a skin cancer, and one in every five Americans will develop skin cancer in their lifetime. North America has well-developed healthcare infrastructure with massive investment in research and development of oncolytic virus immunotherapy.
In 2018, the global Oncolytic Virus Immunotherapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Oncolytic Virus Immunotherapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oncolytic Virus Immunotherapy development in United States, Europe and China.
The key players covered in this study
Shanghai Sunway Biotech
Market segment by Type, the product can be split into
Engineering Oncolytic Viruses
Wild-Type Oncolytic Viruses
Market segment by Application, split into
Ambulatory Surgical Centers
Central & South America
The study objectives of this report are:
To analyze global Oncolytic Virus Immunotherapy status, future forecast, growth opportunity, key market and key players.
To present the Oncolytic Virus Immunotherapy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Oncolytic Virus Immunotherapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.